HAB Pharma plans to achieve Rs 3,000 Cr worth revenue by 2030

Mumbai-based HAB Pharma aims to scale its revenues to Rs 2,500-3,000 crore by 2030, driven by expanded manufacturing capacity, strengthened R&D capabilities, and a focus on off-patent molecules and complex dosage forms.

The company continues to build on its legacy of providing affordable, high-quality medicines, particularly for general practitioners in India, while enhancing its presence in international markets.

HAB Pharma and Signature Phytochemicals have completed a strategic merger through a slump sale, bringing both companies under a single consolidated entity. Finalised in March 2026, the merger was undertaken to streamline operations, harmonize corporate systems, and strengthen governance, positioning the combined company for future growth and operational efficiency. The consolidated turnover is approximately Rs 600 crore after accounting for intercompany sales.

HAB Pharmaceuticals is commissioning two new manufacturing plants: a sterile facility focused on semaglutide, prefilled syringes, injectables, vials, and lyophilised products, and a fully automated closed-loop oral solid dosage (OSD) plant. Both plants are expected to commence commercial production by August 2026. These facilities will enhance the company’s capacity to meet growing demand, support regulatory approvals, and expand its presence in Southeast Asia, Latin America, and Africa, where it has already been audited by regulators in Uganda, Tanzania, and Iraq.